Navigation Links
Highly specialized, minimally invasive surgery for lung cancer allows patient to go home sooner
Date:10/28/2008

Philadelphia -- Minimally-invasive surgery for lung cancer called video-assisted thoracic surgery or VATS is a relatively new procedure performed almost exclusively at academic centers. Now, a preliminary study to be presented this month at the annual CHEST meeting in Philadelphia is giving surgeons an early look at its benefits.

Conventional or open surgery for lung cancer requires a six to 10-inch incision, cutting the major muscles overlying the chest. The surgeon spreads the ribs apart with a retractor in order to view and gain access to the lung, sometimes even removing a portion of one rib. With open surgery or VATS, the surgeon removes either a section of the lung or the affected lobe.

VATS is performed with two to four small incisions (the main incision is only 2 inches long). Instead of spreading the ribs, the surgeon gains access to the lungs through a space between the ribs. By inserting a small camera, the surgeon has a magnified view of the organs on a monitor in the operating room.

"Anecdotally, we've observed similar outcomes with open surgery and VATS, but we've seen a significant advantage with VATS concerning quality of life matters," says Walter Scott, M.D., a thoracic surgeon at Fox Chase Cancer Center, one of few surgeons in the country who performs this highly-specialized surgery. "Now, we have well-analyzed comparison data that supports what we've observed in our patients."

For the study, Scott and his colleagues analyzed the records of 140 lobectomy patients who underwent VATS (74 patients) and open surgery (66 patients) for stage I non-small cell lung cancer. Five of the 74 VATS lobectomies were converted to open procedures. Operative mortality was 1/66 (1.5 percent) for open surgery and 1/74 (1.5 percent) for VATS.

"The most exciting finding is that our patients go home much sooner when they have VATS compared to open surgery," Scott says. The post-operative hospital stay was four days for VATS patients and seven days for open surgery patients (P<0.0001).

"VATS patients also had the post-operative chest tube removed sooner than patients with open surgery," he says. Adjusted median chest tube duration was 5 days for open surgery versus 4 days for VATS (P<0.0001) The percentage of patients with any complication was 42 percent for open surgery versus 35 percent for VATS (P=0.516).

Scott says the new study shows VATS allows the same comprehensive approach to removing the cancer as open surgery. "Removing all of the cancer is always our main goal which includes the removal of lymph nodes." Adjusted mean lymph nodes stations (#/patient) was 4.6 (open) versus 4.2 (VATS), p=0.249. Adjusted mean number of lymph nodes per patient was 18.1 (open) versus 14.7 (VATS), p=0.145. (Walter, the last couple of sentences here are clunky and contain too much jargon. Can you help me out by translating this?)

"Minimally invasive surgical techniques have been used for many decades, but only recently have we applied the technology to patients with lung cancer," Scott says. "This study is important in demonstrating the effectiveness and the reduced impact it can have for our patients."


'/>"/>

Contact: Karen Mallet
karen.mallet@fccc.edu
215-514-9751
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Highly-specialized, minimally-invasive surgery for lung cancer allows patient to go home sooner
2. Derma Sciences Announces 3-Year Licensing Deals for Highly Profitable Character Strip Bandages
3. CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) : Highly encouraging registry data also presented at TCT 2008
4. MD2 International Brings Highly Attentive Medicine to Chicago
5. Lincoln Park Performing Arts Center to Host Highly Acclaimed Music and Medicine Program
6. Endoscopic ultrasound highly accurate in evaluating ambiguous radiographic findings of the pancreas
7. Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
8. OptiNose presents data on highly effective migraine treatment
9. The HealthCentral Network Acquires MedTrackAlert, Extending its Ability to Reach Highly Engaged Online Health Consumers
10. Self-Monitoring of Blood Glucose Highly Effective in Diabetes Care, According to a Special Issue of Diabetes Technology and Therapeutics
11. Breast-Specific Gamma Imaging (BSGI) Found to Be Highly Sensitive for Early Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating its ... location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There ... TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, DDS, ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. ... Potter -- are proud of the recent release of their 2014 in vitro fertilization ... published the latest verified data for 375 U.S. member clinics. *Preliminary data shows ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
Breaking Medicine Technology: